Edition:
United Kingdom

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

51.53USD
17 Jan 2018
Change (% chg)

$0.21 (+0.41%)
Prev Close
$51.32
Open
$51.87
Day's High
$52.35
Day's Low
$51.00
Volume
271,933
Avg. Vol
261,299
52-wk High
$91.75
52-wk Low
$41.06

Latest Key Developments (Source: Significant Developments)

Spark Therapeutics To Begin Program In Pompe Disease
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Spark Therapeutics ::SPARK THERAPEUTICS CEO SAYS PLANS TO BEGIN PROGRAM IN POMPE DISEASE.SPARK CEO SAYS EXPECTS LUXTURNA GENE THERAPY TO BE AVAILABLE TO PATIENTS IN EUROPE IN 2019.  Full Article

Spark Therapeutics - On Jan 3, 2018, Co Announced Wholesale Acquisition Cost For Luxturna Is $425,000/Dose
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS - ON JAN 3, 2018, CO ANNOUNCED WHOLESALE ACQUISITION COST FOR LUXTURNA (VORETIGENE NEPARVOVEC-RZYL) IS $425,000/DOSE OR PER EYE.  Full Article

FDA Approves Luxturna, A Gene Therapy To Treat A Rare Form Of Vision Loss
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVES LUXTURNA (VORETIGENE NEPARVOVEC-RZYL), A GENE THERAPY TO TREAT PATIENTS WITH A RARE FORM OF INHERITED VISION LOSS.U.S FDA SAYS GRANTED APPROVAL OF LUXTURNA TO SPARK THERAPEUTICS INC.U.S. FDA SAYS LUXTURNA IS APPROVED FOR THE TREATMENT OF PATIENTS WITH CONFIRMED BIALLELIC RPE65 MUTATION-ASSOCIATED RETINAL DYSTROPHY.  Full Article

Spark Therapeutics reports Q3 loss per share $1.90
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics Inc reports third quarter 2017 financial results and recent business progress.Q3 loss per share $1.90.Q3 earnings per share view $-1.81 -- Thomson Reuters I/B/E/S.  Full Article

Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B.Spark Therapeutics Inc - Co transferring enhanced SPK-9001 manufacturing process to Pfizer.Spark Therapeutics - Co, Pfizer ‍have entered into amendment to their license agreement for SPK-9001.Spark Therapeutics - ‍Subject to terms of amendment, Spark Therapeutics will receive from pfizer an initial $10 million cash payment​.Spark Therapeutics Inc - Will enroll up to five additional participants in current phase 1/2 clinical trial​.Spark - ‍Subject to amendment, to receive from Pfizer up to additional $15 million in potential milestone payments upon completion of transition activities​.Spark Therapeutics - ‍Activities outlined in amended agreement will occur parallel to Pfizer's ongoing preparation to assume responsibility for SPK-9001.  Full Article

Spark Therapeutics says NASDAQ halts trading of its common stock
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Spark Therapeutics Inc : :Spark Therapeutics (once) trading of stock halted as FDA advisory committee reviews investigational gene therapy.Spark Therapeutics Inc - U.S. ‍FDA's cellular, tissue and gene therapies advisory committee is meeting today to review LUXTURNA (voretigene neparvovec)​.Spark Therapeutics Inc - ‍LUXTURNA is under priority review with FDA, with an assigned prescription drug user fee act (PDUFA) date of jan. 12, 2018​.  Full Article

Spark Therapeutics Q2 loss per share $1.04
Wednesday, 10 Aug 2016 

Spark Therapeutics Inc : Q2 loss per share $1.04 . Spark therapeutics reports second quarter 2016 financial results and recent business highlights . Q2 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S . Q2 revenue $1.3 million versus $1.3 million .Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.  Full Article

Spark says announces publication of positive follow-up data from phase 1 trial of voretigene neparvovec in The Lancet
Friday, 1 Jul 2016 

Spark Therapeutics Inc : Says has initiated a rolling submission of bla with fda on voretigene neparvovec .Spark therapeutics announces publication of positive follow-up data from phase 1 trial of voretigene neparvovec in the lancet.  Full Article

Spark Therapeutics public offering of 3.50 mln shares priced at $45/shr
Wednesday, 15 Jun 2016 

Spark Therapeutics Inc : Spark Therapeutics announces pricing of public offering .Says public offering of 3.50 million common shares priced at $45.00per share.  Full Article

Spark Therapeutics files for potential mixed shelf offering
Monday, 13 Jun 2016 

Spark Therapeutics Inc :Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

Photo

Drugmakers see a pricing blueprint in an $850,000 gene therapy

SAN FRANCISCO Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.